Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07059832

Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

The First Hospital of China Medical University

Shenyang, Liaoning, China

About this study

The aim of this study was to explore the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in patients with solid tumors or lymphoma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who were diagnosed with malignant tumors;
  • Patients are between 18 and 80 years of age are between 18 and 80 years of age.

Exclusion criteria

  • Participants who were unable or unwilling to provide written informed consent.
  • Participants who were unable to successfully complete the examination and are forced to abort the test in the middle of the test

Treatment and study plan

68Ga-NODAGA-SNA006

Drug

68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.

Primary outcomes

  1. Incidence of 68Ga-NODAGA-SNA006-emergent Adverse Events

    Time frame: 3 YEAR

    Through PET/CT, Visual analysis was positive, or the SUVmax was more than the mediastinum

  2. Biodistribution of 68Ga-NODAGA-SNA006

    Time frame: 3 YEAR

    Through PET/CT analysis, SUVmax and SUVmean of the organs

Secondary outcomes

  1. Correlation analysis of 68Ga-NODAGA-SNA006 uptake and tumor immune phenotype

    Time frame: 3 YEAR

    Correlation coefficients (r²) between SUVmax and SUVmean measured by PET/CT and immunophenotypes

Sponsors and collaborators

Lead sponsor

First Hospital of China Medical University

Other

Registry information

Official study title

Application of 68Ga-NODAGA-SNA006 in Patients With Solid Tumor or Lymphoma

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Jul 11, 2025
Registry last updated
Jul 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.